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 ABSTRACT 
Tumor blood vasculature tends to be heterogeneously distributed, densely branched, tortuous, 
malformed, and hyperpermeable relative to that found within physiological tissues. Furthermore, 
tumors are known to stiffen as they progress, a phenomenon that has largely been attributed to 
heightened extracellular matrix protein cross-linking. As cells are capable of sensing and 
responding to the stiffness of their surrounding matrix via mechanisms that include changes in 
the phosphorylation of focal adhesion proteins, like FAK and Src, we hypothesized that there is a 
relationship between abnormal tumor vasculature characteristics and tumor stiffening.  
By grafting glycated collagen constructs to the chorioallantoic membranes of chicken embryos 
cultured ex ovo, and with two- and three-dimensional human umbilical vein endothelial cell 
culture systems, we show that increasing the stiffness of a tissue significantly enhances the 
extent of angiogenic vascularization it experiences, and that neovessels or monolayers formed 
within stiff tissues or on stiff substrates are significantly more permeable than their compliant 
counterparts. Furthermore, we demonstrated that membrane type-one matrix metalloproteinase 
activity inhibition can nullify the effect that matrix stiffening has on vascularization ex ovo, and 
that inhibiting the phosphorylation of FAK tyrosine residue 397 (Y397) can alleviate stiffness-
induced hyperpermeability in vitro and ex ovo. Using western blotting techniques, we show that 
Src Y418 and VE-cadherin Y685 phosphorylation significantly increase with increasing matrix 
stiffness, and that FAK inhibition prevents the latter from occurring. Together, these data 
indicate that matrix stiffening promotes the phosphorylation of Src, and that Src interacts with 
activated FAK to phosphorylate tyrosine residues on the cytoplasmic tail of VE-cadherin, which 
regulate endothelial barrier junction integrity via the mediation of catenin attachment. We 
conclude by suggesting co-treatments to enhance the efficacy of existing chemotherapeutics, and 
by conceptualizing future projects that expand upon the work presented here. 
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CHAPTER 1 
INTRODUCTION 
1.1 Abnormal Tumor Vasculature  
 The American Cancer Society estimates that nearly six-hundred thousand Americans will 
succumb to cancer in 2016, making it the second leading cause of death within the United 
States.
1
 Cancer is characterized by the dysregulated growth of malignant neoplasms, or tumor-
forming masses of invasive cells. If limited to known, accessible regions of the body, cancerous 
tissue can be excised. However, the majority (≥90%) of cancer-related deaths are attributed to 
complications caused by secondary tumors, which arise from metastasis.
2,3
 Therefore, most 
existing cancer treatment methods, including chemotherapy and immunotherapy, hormone 
therapy, and targeted therapy, rely heavily on the use of systemic agents to combat malignant 
cells.
4,5
 These are often administered alongside radiotherapy, the efficacy of which is a function 
of cell oxygenation, and photodynamic therapy, which utilizes systemic photosensitizers.
4–6
 
Within tumors, vasculature with abnormal characteristics generates physical and biochemical 
conditions that resist the entry of systemic agents, drive metastasis, and alter cell phenotypes.
7,8
 
 Tumor blood vasculature tends to be heterogeneously distributed, densely branched, 
tortuous, malformed, and hyperpermeable relative to that found within physiological tissues.
9,10
 
Due to a large number of leaky vessels, the interstitial space fills with fluid. Without functional 
lymphatic vessels to drain this fluid, and in conjunction with tumor cell proliferation and 
elevated extracellular matrix (ECM) protein deposition, interstitial pressures surpass venous 
pressures, leading to vessel collapse and flow stasis or reversal.
9,11
 This exasperates flow rate 
issues precipitated by excessive branching, tortuosity, malformations, and elevated intratumoral 
blood viscosities.
9–12
 As a result, convective flow through and extravasation into tumors, the 
primary driving forces behind drug transport, are largely absent. In fact, as interstitial pressure 
drops to normal levels at the periphery, flow tends to evade tumors, as evident by their hypoxic, 
2 
 
acidic cores.
7,9
 This limits intratumoral drug transport to diffusion, which faces an excessive 
collagen-rich extracellular matrix, and which must reach regions that lack vasculature.
7
 Thus, 
systemic drugs can pass through the body without ever penetrating the tumor.
7,13
 Equivalently, 
the entry of lymphocytes responsible for eliminating dysfunctional cells is also hindered, and the 
function of those that do enter are impaired by hypoxic and acidic conditions.
14
 In contrast, 
outward flow through compromised vessels facilitates the escape of metastatic cells, and a 
hypoxic environment promotes invasive phenotypes.
14
 
 Angiogenesis, the physiological process by which new vascular networks sprout from 
existing ones, is a process mediated by numerous pro- and anti- angiogenic factors.
15
 In the early 
1970s, Judah Folkman identified that solid tumor growth beyond a few millimeters, the size 
above which the diffusion of nutrients and oxygen becomes inadequate, requires the presence of 
local vasculature, and thus is the limiting factor in tumor growth.
16
 Based on this observation, he 
hypothesized that suspending tumors in a nonvascularized state via anti-angiogenic therapy 
would isolate metastasizing cells from the rest of the body, enhance the efficacy of 
chemotherapeutics, and facilitate immunologic attacks.
17
 However, it has since been shown that 
disrupting tumor vasculature has the opposite effect: it introduces hypoxia, which fuels tumor 
growth and aggression, it removes the infrastructure that systemic agents rely on to infiltrate 
tissue, and it generates a microenvironment that impairs immune cell entry and function.
14
 The 
field now believes that the meager improvements observed in the prognosis of patients receiving 
anti-angiogenic therapy may be attributed to brief periods of vascular normalization.
14,18
 
1.2 Tumor Stiffening 
 In addition to possessing abnormal vasculature, tumors also stiffen as they progress; the 
elastic moduli of some tumors rise to manyfold that of healthy tissue.
19
 This stiffening has been 
attributed to increased extracellular matrix protein deposition, cell crowding, fluid accumulation, 
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matrix remodeling, and elevated ECM protein cross-linking.
20
 Of these, the cross-linking of 
ECM proteins, namely collagen, is believed to drive matrix stiffening.
21
 
 In healthy tissues, collagen, the most abundant protein in the human body, forms 
networks of fibers that provide tissue with its tensile strength.
22
 As tissues age, the aldehyde 
groups of reducing sugars, like glucose and ribose, react non-enzymatically with the free amino 
groups of lysine and arginine residues of collagen to form Schiff bases, which can spontaneously 
rearrange into Amadori products, which can undergo further reactions to form a variety of 
advanced glycation end-products (AGEs), which can form intramolecular covalent cross-links 
with other AGE-containing proteins.
23
 Owing to the hypoxic nature of tumor tissue, which 
restricts the cells within them from performing aerobic respiration, tumors uptake and process 
glucose at a higher rate than normal tissues via anaerobic glycolysis, suggesting an increase in 
AGE formation.
24
 Collagen fibers can also be enzymatically cross-linked via lysyl oxidase 
(LOX), which oxidizes collagen lysine and arginine residues to α-aminoadipic-δ-semialdehydes, 
which spontaneously condense to form intramolecular covalent cross-links with similarly 
affected fibers.
25
 Increases in LOX expression and secretion have been linked to hypoxia, and is 
largely regarded as the driving force responsible for tumor stiffening and progression.
21,26–28
 
 Over the past two decades, significant evidence indicating that cells are capable of 
sensing and responding to the mechanical properties of their surrounding extracellular matrix has 
emerged.
29,30
 Notably, changes in ECM stiffness can influence cell differentiation, gene and 
protein expression, proliferation, survival, spreading, polarization, adhesion, migration, and cell-
cell interactions.
31
 Cells adhere to and sense surrounding matrix proteins via integrin receptors, 
which cluster and link to the actin cytoskeleton through multi-protein focal adhesion 
complexes.
30
 In addition to providing scaffolding functions, many of these proteins participate in 
numerous signaling pathways. Of these, focal adhesion kinase (FAK) and proto-oncogene 
tyrosine-protein kinase (Src) have been implicated in stiffness-sensing mechanisms.
32,33
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1.3 Relationship Between Tumor Stiffening and Abnormal Tumor Vasculature 
 The aberration of tumor vascular characteristics is commonly attributed to an increased 
presence of pro-angiogenic factors, including, but not limited to, vascular endothelial growth 
factors (VEGFs), fibroblast growth factors (FGFs), hypoxia-inducible factors (HIFs), platelet-
derived growth factors (PDGFs), and angiopoietins.
34
 Therefore, vascular normalization experts 
advocate the judicious administration of anti-angiogenic agents, hypothesizing that doing so will 
counteract the excessive angiogenic stimuli that upset the balance of the process, which 
ultimately leads to the formation of abnormal vasculature.
35
 These attempts have met with 
limited success, typically only extending patient life by weeks to months when used in 
conjunction with existing chemotherapeutics.
8,14
 However, angiogenesis is a product of multiple 
stiffness-dependent cell processes, including proliferation, differentiation, polarization, adhesion, 
and migration.
15,36,37
 Therefore, it, too, is likely influenced by tissue stiffness. 
 Recent efforts to investigate the effect that tissue stiffness has on angiogenesis in the 
context of tumor stiffening have largely relied upon the manipulation of construct density and 
composition.
38–40
 These studies reported decreases in angiogenic outgrowth and vascular 
network formation with increasing tissue stiffness. However, as ECM protein density is 
inherently linked to matrix architecture, porosity, and the number of available integrin binding 
sites, all of which influence cell functions involved in angiogenesis, the influence that matrix 
stiffness has on angiogenesis could not be singled out.
41
 Furthermore, recent work published by 
our lab revealed that bovine aortic endothelial cells (BAECs) embedded in cross-linked collagen 
gels exhibit enhanced angiogenic outgrowth relative to those embedded in compliant gels.
41
 
Therefore, this project begins with an investigation into the effect that collagen fiber cross-
linking has on angiogenic vascularization. Furthermore, as matrix stiffness has been shown to 
influence the activity of membrane-type 1 matrix metalloproteinase (MT1-MMP, or MMP14), a 
mediator of angiogenesis, its role on stiffness-dependent vascularization was determined.
42–44
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 In the context of arteriosclerosis, prior work published by our lab suggested that 
stiffening of the arterial intima, which occurs naturally with age, leads to increases in vascular 
permeability.
45
 This was achieved by seeding BAECs on synthetic two-dimensional (2D) 
polyacrylamide gels functionalized with collagen, and by means of an Evan's blue permeability 
assay in young and old mice. The intima consists of a one-cell-thick lining of endothelial cells 
surrounded by a thin basement membrane, which, in large vessels, is composed of collagen, 
elastin, and proteoglycans.
46,47
 While the intima of arteries and veins are surrounded by a media 
composed mainly of smooth muscle cells (SMCs), and by an adventitia composed of connective 
tissue, that of angiogenic neovessels and tumor microvessels only receives partial shelter from 
pericytes.
48,49
 Therefore, not only is the extracellular component of their intima exposed to the 
same cross-linking reactions taking place within the tumor stroma, but the endothelial lining 
within it has little cushion from the forces imposed by the surrounding tumor matrix. That 
motivation established, this project proceeds with an investigation into the effect that matrix 
stiffness, independent of matrix density, has on the permeability of tumor vessels. 
1.4 Potential Targets in Normalizing Stiffness-Dependent Vascular Permeability 
 Outside of the blood-brain barrier, endothelial cells within blood vessels adhere to one 
another and regulate permeability via adherens junctions, which are maintained by vascular 
endothelial (VE)-cadherin.
50
 Since our lab has previously shown that increasing matrix stiffness 
disrupts endothelial barrier junction integrity, we sought to uncover the mechanism responsible 
for stiffness-induced permeability.
45
 Furthermore, it has been well established that the 
phosphorylation of VE-cadherin's cytoplasmic tail mediates vascular permeability. Tyrosine 
residue 658 (Y658) phosphorylation disrupts the binding of the junction stabilizer proteins p120-
catenin and β-catenin, resulting in junction disassembly and a decrease in endothelial barrier 
function.
51–55
 Phosphorylation of a separate tyrosine residue, Y685, has also been found to 
trigger vascular permeability.
51,52,56
 Relevantly, phosphorylation of FAK Y397 and Src Y418 
have been shown to directly phosphorylate VE-cadherin residues Y658 and Y685.
33,56–58
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 Increases in the expression and activity of FAK and Src, two cytoplasmic protein tyrosine 
kinases that associate with focal adhesions and participate in numerous signaling pathways, has 
been correlated to poor prognosis in cancer patients.
59–62
 Phosphorylation of FAK Y397, which 
has been reported to increase with matrix stiffness, as well as in response to integrin engagement, 
recruits Src to focal adhesions, where both undergo additional phosphorylation events.
59–62
 In 
multiple studies, FAK and Src have been reported as mediators of vascular permeability.
63–67
 
Because FAK Y397 itself has been implicated in influencing vascular permeability, and because 
it recruits and activates Src, as well as forms FAK-Src complexes that trigger additional 
phosphorylation events, we chose to investigate the ability of PF573228, an inhibitor of FAK 
Y397 phosphorylation, to restore the integrity of leaky neovessels.
61,62,68–71
  
1.5 Project Overview 
 Based on what is known about tumor stiffening and abnormal tumor vasculature, we 
hypothesized that angiogenesis is mediated by extracellular matrix stiffness, and that the extent 
to which a tissue experiences angiogenic vascularization is a function of its stiffness. To 
investigate the effect that matrix stiffness has on angiogenic vascularization, constructs 
containing collagen gels of various stiffness were grafted to the chorioallantoic membranes 
(CAMs) of chicken embryos cultured ex ovo on day 10 of embryonic development (ED10). 
Collagen stiffness was mediated by initiating non-enzymatic glycation reactions with ribose prior 
to gel polymerization, which produced three-fold increases in gel equilibrium compressive 
modulus without producing significant changes in fiber architecture.
72
 These glycated collagen 
gels were infused with VEGF and basic FGF (bFGF) to induce angiogenesis, and constructs 
were formed by sandwiching the gel between nylon meshes to separate the gel from existing 
vasculature, as well as to provide a grid for quantification.
73
 On ED13, neovessels were counted 
with the aid of a stereoscope, and vascular density was defined as the percentage of squares 
within the grid containing vasculature. From these experiments, we found that stiffer constructs 
contained significantly denser vascular networks than their compliant counterparts. To 
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investigate the role that MT1-MMP activity plays in stiffness-dependent vascularization, 
GM6001, an inhibitor of MMP activity, was introduced to select constructs. Interestingly, we 
found that while MMP inhibition has no effect on the vascularization of compliant constructs, it 
reduces the vascularization of stiff constructs to compliant construct levels. 
 Furthermore, we hypothesized that angiogenic neovessel and tumor blood microvessel 
endothelial barrier integrity is a function of extracellular matrix stiffness, and that vascular 
permeability increases with increasing matrix stiffness. To investigate the effect that matrix 
stiffness has on endothelial barrier integrity, an in vitro monolayer permeability assay was 
conducted on human umbilical vein endothelial cell (HUVEC) monolayers grown on compliant 
and stiff collagen-functionalized polyacrylamide (PA) gel substrates. To quantify monolayer 
permeability, endothelial cell (EC) monolayers were introduced to media containing 40 kDa 
fluorescein isothiocyanate (FITC)-dextran, and confocal laser scanning microscopy (LSM) was 
used to capture the fluorescent signal intensity above and below the monolayer after a set time. 
Following analysis, we found that increasing substrate stiffness yields significantly leaker 
HUVEC monolayers. To further investigate the effect that matrix stiffness has on vascular 
permeability, we developed a novel assay to quantify the permeability of chicken embryo CAM 
angiogenic neovessels grown within grafted collagen constructs. This was achieved by injecting 
fifteen day old chicken embryos with a mixture of 2 MDa FITC-dextran and 65-85 kDa 
tetramethylrhodamine (TRITC)-dextran, and multi-photon microscopy (MPM) was used to 
identify neovessels and to record fluorescent dye extravasation over time. Following analysis, we 
found that stiffer constructs contained significantly leakier neovessels than their compliant 
counterparts. To substantiate the validity of our model, positive control samples were generated 
by introducing VEGF, which is known to induce hyperpermeability, to the injection mixture.
74
 
We found that, regardless of construct stiffness, the neovessels of chicken embryos injected with 
VEGF became significantly more leaky.  
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 Motivated by findings that matrix stiffness can disrupt vascular permeability, we decided 
to investigate the ability of PF573228, an inhibitor of FAK Y397 phosphorylation, to restore the 
integrity of leaky endothelial barriers in contact with stiff matrices. By running in vitro 
monolayer permeability assays on HUVEC monolayers grown on collagen-functionalized PA 
gels, we found that treatment with PF573228 significantly reduces the permeability of 
monolayers grown on stiff substrates, but does not influence that of those grown on compliant 
ones. Inspired by these findings, we applied PF573228 to collagen constructs grafted to the 
CAMs of chicken embryos cultured ex ovo, and quantified the effect that FAK inhibition has on 
neovessel permeability. Surprisingly, we found PF573228 capable of reducing the permeability 
of neovessels within stiff constructs to compliant construct levels. 
 Finally, we decided to investigate the mechanism responsible stiffness-sensitive vascular 
permeability. To accomplish this, western blotting techniques were applied to compliant and stiff 
HUVEC-infused glycated collagen gels, some treated with PF573228. Because we hypothesized 
that stiffness-induced hyperpermeability is elicited by the phosphorylation of VE-cadherin's 
cytoplasmic tail, which FAK and Src activity are known to mediate, we decided to probe FAK, 
Src, and VE-cadherin phosphorylation as a function of matrix stiffness and FAK inhibition. We 
verified that PF573228 inhibits FAK Y397 phosphorylation, as intended. Furthermore, we found 
that Src Y418 and VE-cadherin Y685 phosphorylation significantly increase with increasing 
matrix stiffness, and that FAK inhibition prevents the latter from occurring.  
 Additional experiments were conducted over the course of this project, including an 
investigation into the effect that collagen cross-linking via glutaraldehyde has on angiogenic 
outgrowth ex ovo, the effect that β-aminopropionitrile (BAPN) has on EC monolayer 
permeability in vitro, and the effect that matrix stiffness via collagen cross-linking has on MT1-
MMP expression and activity in ECs cultured within glycated collagen gels. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 In Vitro Techniques 
2.1.1 Cell Culture 
 Human umbilical vein endothelial cells were purchased from Lonza, subcultured, split 
into 1 mL aliquots containing 1,000,000 passage three (P3) cells, and frozen in liquid nitrogen 
prior to use. Endothelial growth media (EGM) was prepared by adding contents of Lonza EGM 
BulletKit™, which contained 0.5 mL human endothelial growth factor, 0.5 mL hydrocortisone, 
0.5 mL acetic acid, 0.5 mL GA-1000 antibiotic antifungal solution, 2 mL bovine brain extract, 
and 10 mL fetal bovine serum, to endothelial basal media. HUVECs were cultured in EGM, 
which was replaced every 48 hours, and incubated at 37°C, 5% CO2. Subculture was conducted 
using trypsin enzyme, trypsin neutralizer, and a 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) wash solution containing 25 mM HEPES and 44 mM sodium bicarbonate in 
phosphate-buffered saline (PBS) prior to 100% confluence, and prior to P7. 
2.1.2 Production of Collagen-Functionalized Polyacrylamide Gel Coated Glass Coverslips 
 Glass 18 x 18 mm coverslips were first activated by undergoing 2 minutes of plasma 
cleaning, 10 minutes of incubation in Milli-Q (MQ) water containing 1% polyethylenimine, three 
5 minute MQ water washes, air drying, 30 minutes of incubation on PBS containing 0.1% 
glutaraldehyde, three 5 minute MQ water washes, and then allowed to air dry. 
 Polyacrylamide gels were prepared by combining 40% acrylamide, bis-acrylamide, 
HEPES in MQ water at pH 6, tetramethylethylenediamine (TEMED), and MQ water, adjusting 
the pH of the solution to 6 using HCl, and degassing the solution to remove oxygen, which 
would otherwise inhibit polymerization from occurring in a later step. N-6-((acryloyl)amido) 
hexanoic acid (N6) dissolved in ethanol (EtOH) was added to the solution to enable attachment 
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of collagen in a later step. PA gel stiffness was controlled by adjusting the ratio of 40% 
acrylamide to bis-acrylamide, as described previously by our lab and by others.
75,76
 Ammonium 
persulfate (APS) dissolved in MQ water was added to the solution, initiating polymerization, 
which was then immediately pipetted onto activated square glass coverslips and covered by 
circular 18 mm diameter glass coverslips coated in Rain-X. Once PA gels were polymerized, 
circular coverslips were removed, and square glass coverslips coated in PA were inverted onto 
droplets of 0.1 mg∙ml-1 rat tail tendon (RTT) collagen type I in 50 mM HEPES solution at pH 8 
on flat Parafilm. Following collagen polymerization, gels were inverted onto droplets of 1:1000 
ethanolamine in 50 mM HEPES solution at pH 8 on flat Parafilm to cap unreacted N6. Square 
glass coverslips coated with PA gels functionalized with collagen were washed in PBS, then 
stored at 4°C in a PBS solution containing 5% Penicillin Streptomycin and 1% amphotericin B 
until cell seeding. This procedure is similar to one described previously by our lab.
75
 
2.1.3 Monolayer Permeability Assay 
 Square glass coverslips coated with PA gels functionalized with collagen were moved to 
a sterile laminar flow hood, placed in wells of uncovered 6-well plates containing sterile PBS, 
and exposed to UV light for 30 minutes. HUVECs suspended in EGM were prepared with a 
concentration of 50,000 to 100,000 cells per mL, and 2 mL of this solution was added to each PA 
gel. HUVECs were allowed to form confluent monolayers over a period of 5 to 7 days with 
media replacement every 48 hours. To some samples, EGM containing PF573228, BAPN, or 
dimethyl sulfoxide (DMSO) was added 24 hours prior to the start of the assay. 
 On the day of the assay, a 0.4 mg∙mL-1 40 kDa FITC-dextran solution was prepared in 
EGM. Per seeded PA gel, 4 mL of this solution was added to a 35 mm MatTek glass-bottomed 
dish, all of which were stored in an incubator at 37°C, 5% CO2. One at a time, seeded PA gels 
were transferred to filled MatTek dishes and visualized using a Zeiss LSM700 equipped with a 
C-Apochromat 40x/1.1 W Corr water immersion objective. Five minutes after submersion in 
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FITC-dextran solution, a vertical line scan was captured at the center of the seeded PA gel, 
spanning from 200 μm below the monolayer to 100 μm above the monolayer. 
 Monolayer permeability was quantified by calculating the normalized intensity ratio 
(NIR). First, the intensity ratio (IR) was determined by dividing the FITC signal intensity within 
the gel (below the monolayer) by that within the fluorescent solution (above the monolayer). To 
produce NIR values, the IR values of seeded PA gels were divided by the IR values of unseeded 
control PA gels, as previously described by our lab (Figure 1).
45
 
 
Figure 1: HUVEC-seeded 10 kDa PA gel submerged in FITC-dextran 
solution. Cell monolayer outlined in white, and regions of interest 
(ROIs) used in data analysis shown in yellow. IR calculated by 
dividing the lower ROI intensity by the upper ROI intensity. 
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2.1.4 HUVEC-Infused Glycated Collagen Gel Preparation 
 To form "stiff" glycated collagen gels, 150 μL of 10 mg∙mL-1 RTT collagen type I in 
0.1% acetic acid (AA) was mixed with 527 μL of 0.1% AA and 169 μL of 500 mM ribose in 
0.1% AA on ice in a laminar flow hood, then incubated at 4°C for 5 days to permit non-
enzymatic glycation reactions to occur, leading to the formation of cross-links between collagen 
fibers. To form "compliant" collagen gels, 150 μL of 10 mg∙mL-1 RTT collagen type I in 0.1% 
AA was mixed with 696 μL of 0.1% AA, and also incubated at 4°C for 5 days. After the 
incubation period, 100 μL of a 10X HEPES buffer solution containing 250 mM HEPEs, 440 mM 
NaHCO3, and 0.11 g∙L
-1
 phenol red in 10X PBS was added to each collagen solution, followed 
by 4 μL of 1 M NaOH in MQ water, followed by 50 μL of EGM containing 800,000 HUVECs. 
This produced a HUVEC-infused collagen solution volume of 1 mL, and a final collagen 
concentration of 1.5 mg∙mL-1. Compliant collagen gels formed by this method were previously 
reported to possess a compressive elastic modulus of 175 Pascal, whereas stiff ones were 
previously reported to possess a compressive elastic modulus of 555 Pascal.
41
 
  Into wells of a 24-well plate, 300 μL of HUVEC-infused collagen solution was pipetted. 
These were polymerized via incubation at 37°C, 5% CO2 for 45 minutes. Polymerized gels were 
then submersed in 300 μL of EGM and incubated at 37°C, 5% CO2 for one hour to acclimate. In 
this time, fresh angiogenic media containing 40 ng∙mL VEGF, 40 ng∙mL bFGF, 50 ng∙mL 
tetradecanoyl phorbol acetate, and 50 μg∙mL ascorbic acid in EGM was prepared.38 Following 
the acclimation period, EGM was replaced with angiogenic media, and gels were incubated at 
37°C, 5% CO2 for 24 hours. After the incubation period, gels were transferred to 1.7 mL tubes 
using a pipetter, immediately flash frozen in liquid nitrogen, and stored at -80°C until further 
processing. In some cases, 100 μL collagen gels containing 80,000 cells were prepared in 96-
well plates, which polymerized in 30 minutes, and which were sustained by 100 μL of media. 
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2.1.5 Western Blotting Techniques 
 Per HUVEC-infused glycated collagen gel, a mortar and pestle was washed in alconox, 
submersed in 70% ethanol, air dried, autoclaved, chilled overnight at -80°C, and then filled with 
liquid N2. Each gel was transferred from storage at -80°C to a mortar containing liquid N2. 
Immediately following evaporation of liquid N2, each gel was ground to a fine powder in the 
presence of 150 μL of 6x Laemmli buffer, which was prepared by mixing 6 mL 4x Tris∙Cl/SDS 
at pH 6.8, 3 mL glycerol, 1 gram sodium dodecyl sulfate (SDS), 0.9 mL β-mercaptoethanol, and 
100 μL bromophenol blue. 4x Tris∙Cl/SDS was prepared by mixing 12.1 grams 2-Amino-2-
(hydroxymethyl)propane-1,3-diol (Tris) and 0.8 grams SDS in 80 mL MQ water, adjusting pH 
with HCl, adding MQ water to obtain a volume of 200 mL, and then filtering through a 0.45 μm 
filter. Grinding continued until a liquid solution formed, which was poured into a 1.7 mL tube 
and stored at -80°C until use in a western blot. 
 Four running gels were prepared by mixing 8.4 mL 30% acrylamide/bis and 7.875 mL 4x 
Tris∙Cl/SDS at pH 8.8 with 15.225 mL MQ water, and then degassed for at least 30 minutes. 
While degassing, the Mini-PROTEAN® casting apparatus was assembled per Bio-Rad's 
instructions, with glass plates separated by 1.5 mm.
77
 Following degassing, 21 μL TEMED and 
105 μL 10% APS in MQ water were added to the solution, and 7.4 mL of solution per gel was 
pipetted between glass plates. Gels were immediately covered with 0.5 mL water-saturated 
isobutyl alcohol and allowed to polymerize for 45 minutes. In this time, running and -20°C 
transfer buffers were prepared from 10x stock solutions, as described in Bio-Rad's protocol.
77
 
 Four stacking gels were prepared by mixing 1.95 mL 30% acrylamide/bis and 3.75 mL 
4x Tris∙Cl/SDS at pH 6.8 with 9.15 mL MQ water, and then degassed for at least 15  minutes. 
While degassing, water-saturated isobutyl alcohol was removed from polymerized running gels. 
Following degassing, 15 μL TEMED and 75 μL 10% APS in MQ water were added to the 
solution, and 3 mL of solution per gel was pipetted between glass plates over polymerized 
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running gel. Combs were inserted into stacking gels, which were allowed to polymerize for 30 
minutes. In this time, samples were thawed and heated to 95°C for 5 minutes. 
 Once polymerized, combs were removed from the stacking gel, leaving behind wells. 
Gels sandwiched between glass plates were removed from casting apparatus and assembled into 
running apparatus, to which running buffer was added, per Bio-Rad's instructions.
77
 Each well 
was filled with either 5 μL Kaleidoscope™ Prestained SDS-PAGE Standards ladder (Bio-Rad 
Laboratories), 30 μL sample, or 5 μL 6x Laemmli buffer. Subsequently, electrophoresis was 
conducted at 100 volts for approximately 105 minutes. 
 Following electrophoresis, protein-infused running gel was removed from running 
apparatus and glass plates, cut away from the separating gel, and submerged in chilled transfer 
buffer for at least 5 minutes. In this time, a polyvinylidene difluoride (PVDF) membrane was 
wetted in methanol for 30 seconds, and rocked in chilled transfer buffer for 5 minutes. Once 
acclimated, the protein-infused running gel and PVDF membrane were placed within assembled 
separating apparatus per Bio-Rad's instructions.
78
 Subsequently, electrophoresis was conducted 
within a cold room at 34 volts for 14 hours. 
 Following transfer of proteins from running gel to PVDF membrane, separating apparatus 
was disassembled, and membranes were air dried for 30 minutes. In this time, TBS-t solution 
was prepared by mixing 899 mL MQ water with 1 mL Polysorbate 20 and 100 mL 10x Tris-
buffered saline (TBS) solution, which itself was 100 mM Tris, 1500 mM NaCl in MQ water at 
pH 7.8. Dried membranes were cut and labeled, then wetted in methanol for 30 seconds, then 
washed twice in TBS-t for 10 minutes. In this time, blocking solutions of 5% bovine serum 
albumin (BSA) in TBS-t or 5% milk in TBS-t were prepared. Following washes, membranes 
were rocked at room temperature for one hour or overnight at 4°C. 
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 Primary antibodies (1°abs) were prepared at 1:2000 dilution in 5% milk in the case of 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a housekeeping protein, or at 1:1000 
dilution in 5% BSA in all other cases. Blocked membranes were placed within sealed plastic 
bags containing 3 mL of 1°ab solution, and rocked overnight at 4°C. The next day, 2°abs 
conjugated to horseradish peroxidase were prepared at 1:2000 dilution in the appropriate 
blocking solution while membranes underwent four TBS-t washes. Washed membranes were 
placed within sealed plastic bags containing 3 mL of 2°ab solution, and rocked for one hour at 
room temperature. Following that, membranes underwent four TBS-t washes. 
 Proteins within membranes were imaged using West Pico, Dura, or Femto, per their 
respective protocols, using an ImageQuant™ LAS-4000.79–81 Images were analyzed using the gel 
analysis tool contained within imageJ: Analyze → Gels → Select First Lane applied to a square 
ROI around the first protein band, Select Next Lane applied to square ROIs around all 
subsequent bands (Figure 2A). Per protein band, a histogram was generated via Analyze → Gels 
→ Plot Lanes, background was excluded from the peak via the line tool, and the total protein 
band signal was obtained via the tracing tool (Figure 2B). 
 
Figure 2: (a) Protein bands surrounded by ROIs used in the Analyze → Gels tool within 
imageJ. Brightness and contrast enhanced here to aid in visualization of the technique. 
(b) Histogram of the first band generated by the Analyze → Gels tool with background cut 
away (blue line) and total protein band signal selected (red highlight). 
 
 
 (A)                                (B) 
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 To re-use membranes for the visualization of protein bands with similar molecular 
weights, four TBS-t washes, a 15 minute wash in Restore™ Western Blot Stripping Buffer 
(Thermo Fisher Scientific), four additional TBS-t washes, and incubation in blocking solution 
were conducted prior to the application of additional primary and secondary antibodies. 
 Primary antibodies used in this study includes those for GAPDH (BioLegend, Poly6414), 
FAK (Cell Signaling Technology, 3285S), phospho-FAK-Y397 (Cell Signaling Technology, 
3283S), Src (Cell Signaling Technology, 2108S), phospho-Src-Y418 (EMD Millipore, 07-909), 
VE-cadherin (Santa Cruz Biotechnology, sc-52751), and phospho-VE-cadherin-Y685 
(EMD Millipore, AB1955). Anti-rabbit and anti-mouse secondary antibodies were conjugated to 
horseradish peroxidase. 
2.2 Ex Ovo Techniques 
2.2.1 Chicken Embryo Culture 
 White Leghorn chicken eggs supplied by the Cornell Poultry farm, reachable at phone 
number (607) 272-8970, were cleaned of debris using a dry cloth and stored in a wine cooler at 
12.8°C on ED0 prior to transfer to a GQF 1500 Professional rocking egg incubator maintained at 
37.8 ⁰C, 60% relative humidity. On ED3, eggs were cracked and plied open within a laminar 
flow cabinet using a c-clamp and a hacksaw (Figure 3A). Egg contents were transferred into ex 
ovo culture platforms, which were constructed by slinging a single layer of AEP PVC wrap over 
a 5 oz. Fineline Savvi Serve™ cup partially filled with warm water (Figure 3B). A small scoop 
of autoclaved ground eggshell was distributed around the albumin, and culture platforms were 
capped with a Petri dish lid. Chicks within culture platforms were incubated in Hova-Bator 
circulated air incubators maintained at 37.8 ⁰C, 55% relative humidity.  
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Figure 3: (a) Eggs were slightly squeezed using a c-clamp, then tapped with a hacksaw to form 
a crack. The crack was plied open using the hacksaw tip until albumin began leaking, at which 
point the egg was removed from the c-clamp and pulled apart over an ex-ovo culture platform. 
(b) Ex-ovo culture platform containing living chicken embryo and sterile ground eggshells.  
 
2.2.2 Construction and Grafting of Collagen Constructs 
 As in section 2.1.4, stiff glycated collagen construct formation began with the mixing of 
150 μL of 10 mg∙mL-1 RTT collagen type I in 0.1% AA with 527 μL of 0.1% AA and 169 μL of 
500 mM ribose in 0.1% AA on ice in a laminar flow hood, followed by incubation at 4°C for 5 
days to permit non-enzymatic glycation reactions to occur. Likewise, compliant collagen 
construct formation began with the mixing of 150 μL of 10 mg∙mL-1 RTT collagen type I in 
0.1% acetic acid with 696 μL of 0.1% AA, followed by an incubation at 4°C for 5 days. After the 
incubation period, 100 μL of 10X HEPES buffer solution and 4 μL of 1 M NaOH in MQ water 
were added to each solution. At this point, solutions were infused with RH VEGF 165 (R&D 
Systems) and bFGF (PeproTech) to generate concentrations of 5 μg∙mL-1 and 16.7 μg∙mL-1 
respectively, which have previously been shown to induce angiogenic ingrowth into collagen 
gels.
73
 Select solutions were also infused with MT1-MMP inhibitor GM6001 to generate a 
concentration of 5 μM, which was found by our lab to inhibit the angiogenic outgrowth of 
endothelial cell spheroids.
82
 AA was then added to solutions to produce a final volume of 1 mL.  
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 Onto autoclaved nylon mesh squares with edge lengths approximating five millimeters, 
30 μL of collagen solution was pipetted, which was immediately sandwiched by another nylon 
mesh square. Sandwiched collagen was then polymerized for 30 minutes via incubation at 37°C, 
5% CO2. Immediately following incubation, constructs were placed on the CAMs of ED10 
chicken embryos in a laminar flow cabinet (Figure 4). Chicken embryos were immediately 
returned to their incubators following the procedure. 
 
Figure 4: Chicken embryo to which has been grafted four collagen constructs 
(expanded). Expanded image taken using a Zeiss steREO Discovery.V8 scope. 
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2.2.3 Angiogenic Vascularization Assay 
 On ED13, chicken embryos cultured ex ovo were placed under a Zeiss steREO 
Discovery.V8 scope. As described previously by Nguyen et. al., lens focus was placed on the 
vessels above the bottom mesh, and vascular density was defined as the percentage of mesh 
squares containing vessels.
83
 Peripheral squares were not considered, nor were those under which 
the bottom mesh or collagen gel was not visibly present. 
2.2.4 Neovessel Permeability Assay 
 To preface this section: collagen constructs destined for use in the neovessel permeability 
assay were not formed with a top mesh. On ED15, chicken embryos cultured ex ovo were 
transferred from hammock-styled platforms to Petri dishes. Proximal vessels were injected with 
100 μL of dye solution containing 2.5 mg∙mL-1 65-85 kDa TRITC-dextran (T1162, Sigma-
Aldrich) and 2.5 mg∙mL-1 2 MDa FITC-dextran (FD2000S, Sigma-Aldrich) in PBS. Neovessels 
within collagen constructs were visualized using two-photon microscopy on a Zeiss LSM 880 
upright equipped with a EC Plan-Neofluar 10x/0.3 objective and a Mai Tai laser with a 
wavelength of 900 nm. Fluorescent z-stacks of neovessels, which were identified using the 
FITC-dextran, were taken approximately every 15 minutes for one hour (Figure 5). 
 
Figure 5: 2 MDa FITC-dextran fluorescent signal flowing through neovessels 
grown within a compliant collagen construct 30 minutes post-injection. 
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 Quantification of neovessel permeability began by plotting the fluorescent intensity of the 
TRITC signal across a 20 pixel thick line perpendicular to the neovessel of interest at each time 
point. Intensity values were normalized to the peak value per plot, and peaks were aligned across 
all time points. Then, the integrals under each peak were calculated and plotted as a function of 
time. Neovessel permeability was then defined as the rate of increase of the integral of the 
normalized fluorescent intensity signal (Figure 6). This method was adapted from a paper that 
quantified vascular permeability of large CAM vessels in response to drug administration.
84
 
 
Figure 6: Depiction of neovessel permeability data analysis. At each 
time point, the intensity of the TRITC signal was recorded as a function 
of position along the ROI, and normalized to the peak intensity value, 
which occurred within the neovessel. Then, the integral under each 
curve was calculated. Neovessel permeability was then defined as the 
rate of increase of the integral (outlined in red in this example). 
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CHAPTER 3 
RESULTS 
3.1 Matrix Stiffening Promotes Vascularization in an MT1-MMP Dependent Manner 
 We hypothesized that increasing the stiffness of a tissue's extracellular matrix would 
increase the extent of angiogenic vascularization it experiences. To test our hypothesis, we 
grafted compliant and stiff collagen constructs to the CAMs of chicken embryos cultured ex ovo. 
Apart from glycation induced by addition of ribose, constructs of varying stiffness type were 
identical. Three-days post-grafting, neovessels within the constructs were readily visible 
(Figure 7A), and the percentage of mesh squares containing neovessels was quantified. We 
found that cross-linked collagen gels contained significantly more neovessels than their 
compliant counterparts, shown by an increase in vascular density from 47% ± 6% to 72% ± 5%, 
suggesting that matrix stiffening promotes angiogenic vascularization (Figure 7B). To identify 
whether AGEs were responsible for the increase in vascular density observed in stiff constructs, 
parallel experiments were conducted in which glutaraldehyde was used as a cross-linking agent. 
Still, we found that vascularization significantly increases within gels containing cross-linked 
fibers. This finding was supported by the data of others within the lab, which revealed that 
extensions from HUVEC spheroids embedded within glycated collagen gels were more 
numerous, longer, and consisted of more branching points than those within untreated collagen 
gels, and by additional data indicating that mouse tumors softened with BAPN contained fewer 
vascular branches per image field than did untreated tumors.
82
 
 To investigate the role that MT1-MMP activity plays in stiffness-dependent angiogenic 
vascularization, we infused select constructs with 5 mM GM6001 prior to gel polymerization. 
Analysis of the constructs revealed that inhibition of MMP activity via chelation of the active 
site zinc atom eliminates the stimulating effect that increasing matrix stiffness has on angiogenic 
vascularization, but does not significantly influence compliant gels (Figure 7B).
85
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Figure 7: (a) Image of neovessels within a construct occupying five out of nine mesh squares. 
(b) Vascular density as a function of collagen cross-linking via glycation with 0 or 100 mM ribose, 
and of GM6001 inclusion (ntotal = 80). Data presented as mean ± standard error, with* indicating P < 0.05. 
 
3.2 Matrix Stiffening Induces Vascular Permeability 
 We hypothesized that increasing the stiffness of the extracellular matrix in contact with 
the endothelial monolayer would increase its permeability. To test this hypothesis, we formed 
HUVEC monolayers on collagen-functionalized polyacrylamide gels with elastic moduli of 
2.5 kPa and 10 kPa. Monolayer permeability was assessed by placing the PA gels within glass-
bottomed dishes containing 4 mL of EGM with 0.4 mg∙mL-1 40 kDa FITC-dextran, which was 
selected because its hydrodynamic radius is similar to that of albumin, which has been used by 
other labs to evaluate permeability.
45
 We found that increasing substrate stiffness by four-fold 
increased HUVEC monolayer permeability, represented by an increase in the normalized 
intensity ratio, by 80%, from 0.49 ± 0.016 to 0.88 ± 0.028 (Figure 8A). 
 
(A)                   (B) 
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 Having identified that increasing the stiffness of a 2D substrate increases the permeability 
of the HUVEC monolayer formed on it, we hypothesized that increasing the stiffness of a 3D 
tissue would increase the permeability of the microvasculature within it. To test our hypothesis, 
we adapted a modified version of a technique used to evaluate the effect that systemic drugs have 
on the permeability of large CAM vessels, previously described by Pink et. al., to quantify the 
permeability of angiogenic neovessels within glycated collagen constructs.
84
 Briefly, ED15 
chicken embryos were injected with 100 μL of 2.5 mg∙mL-1 2 MDa FITC and 65-85 kDa TRITC 
dextran, neovessels within collagen constructs were visualized, and z-stacks were taken 
approximately every 15 minutes. Then, TRITC signal intensity as a function of position across 
the neovessel data was acquired at each time point, and normalized to the peak intensity value 
found within the neovessel, and the integral of each of these curve was calculated. Then, vascular 
permeability was defined as the rate of increase of the integrals. Following analysis, we found 
that cross-linking collagen fibers via non-enzymatic glycation, which yields a three-fold increase 
in matrix stiffness, increased permeability by approximately 46% (Figure 8B).  
 To validate our neovessel permeability assay, and to ensure that extravasation of the 
TRITC-signal was not saturated, positive control samples were generated by adding 500 ng of 
VEGF to select injection mixtures, which produced a circulating VEGF concentration of 
approximately 225 ng∙mL-1, which is between four and five times the concentration typically 
used to induce hyperpermeability in vitro.
86,87
 As expected, we found that administration of 
VEGF significantly increased neovessel permeability despite matrix stiffness (Figure 8B). 
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Figure 8: (a) Normalized intensity ratio of HUVEC monolayers seeded on 
compliant (2.5 kPa) and stiff (10 kPa) PA gels (ntotal = 47). (b) Ex ovo 
neovessel permeability assay as a function of collagen cross-linking via 
glycation with 0 or 100 mM ribose, and of VEGF inclusion (ntotal = 70). Data 
presented as mean ± standard error, with * indicating P < 0.05. 
 
 
 
 
(A)      (B) 
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3.3 FAK Inhibition Normalizes the Integrity of Leaky Neovessels Within Stiff Tissues 
 Having identified that matrix stiffness influences vascular permeability, we sought to 
normalize the integrity of leaky neovessels within stiff tissues. Within tumor samples of various 
cancer types, FAK overexpression has been linked to poor patient prognosis, and FAK Y397 
phosphorylation has been correlated to tumor stiffening and progression.
59
 In addition to 
mediating VEGF-induced hyperpermeability, FAK Y397 phosphorylation has been shown to 
directly phosphorylate VE-cadherin Y658, which disrupts junction integrity.
54,57,63,64
 FAK Y397 
phosphorylation also has the potential to indirectly influence permeability via regulation of Rho-
family GTPases, Src, and VE-cadherin accessory molecules.
51,57
 For this reason, we chose to 
evaluate the effect that FAK Y397 inhibition has on permeability in vitro and ex ovo. To achieve 
this, PF573228, a small-molecule that interacts with FAK at the ATP-binding pocket with an 
IC50 of 4 nM in enzyme suspension and 30 nM to 100 nM in cell culture, was employed.
69
 
 To the media sustaining HUVEC monolayers seeded on compliant (2.5 kPa) and 
stiff (10 kPa) PA gels, PF573228 was added 24 hours prior to data collection to produce 
concentrations of 4, 40, 100, and 200 nM. Interestingly, while we found that FAK inhibition 
produced no significant change in the permeability of monolayers formed on compliant 
substrates, it significantly reduced the permeability of those grown on stiff substrates at 
concentrations of 40 nM, 100 nM, and 200 nM (Figure 9A). 
 To evaluate the effect that FAK inhibition has on permeability ex ovo, 30 μL MQ water 
containing 1 μM PF573228 was topically applied to collagen constructs 24 hours prior to data 
collection. Not surprisingly, we found that treatment with PF573228 had no significant effect on 
the permeability of neovessels within compliant matrices (Figure 9B). Surprisingly, however, it 
reduced the permeability of neovessels within stiff constructs to compliant construct levels, 
suggesting that FAK activity is essential to stiffness-induced hyperpermeability (Figure 9B). 
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Figure 9: (a) Normalized intensity ratio of HUVEC monolayers seeded on compliant 
(2.5 kPa) and stiff (10 kPa) PA gels as a function of PF573228 concentration; 40, 100, 
and 200 nM PF573228 significantly reduce monolayer permeability on stiff PA gels 
(ntotal = 118). (b) Ex ovo neovessel permeability assay as a function of collagen cross-
linking via glycation with 0 or 100 mM ribose, and of topical PF573228 application 
(ntotal = 86). Data presented as mean ± standard error, with * indicating P < 0.05. 
 
 
 
 
 
(A)               (B) 
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3.4 Role of FAK and Src Activity in Stiffness-Induced Vascular Permeability 
 Having identified that neovessels grown within stiff cross-linked collagen constructs 
exhibited elevated vascular permeability relative to those grown in compliant constructs, and that 
inhibiting FAK Y397 phosphorylation disrupts this effect, we decided to investigate the 
mechanism responsible. To achieve this, HUVECs were infused within neutralized collagen 
solutions containing ribose at a concentration of 0 or 100 mM, then polymerized within wells of 
a culture plate. Immediately following polymerization, gels were acclimated in EGM for one 
hour, which was subsequently replaced with EGM containing angiogenic growth factors. 
Samples were incubated for 22 hours, at which point angiogenic media was exchanged with that 
infused with PF573228 to produce a concentration of 100 nM, and then incubated for two hours. 
 Following incubation, samples were flash frozen, homogenized via grinding with mortars 
and pestles in the presence of 6x Laemmli buffer, and then subjected to western blotting 
techniques. Three independent sets of HUVEC-infused glycated collagen gels were prepared, 
with each set containing four conditions: compliant control, compliant with PF573228, 
stiff control, and stiff with PF573228, represented by (C) CTRL, (C) PF, (S) CTRL, and (S) PF. 
 To evaluate the effect that matrix stiffness has on FAK expression and phosphorylation, 
and to verify that PF573228 functioned as intended, samples were first analyzed using 
anti-phospho-FAK-Y397 and anti-FAK antibodies (Figure 10A). Though the low intensity of the 
protein bands derived from samples infused with PF573228 made it apparent that the FAK 
inhibitor functioned as intended, we were uncertain whether or not matrix stiffness influenced 
FAK in any way. Therefore, a densitometric analysis was conducted to quantify the amount of 
protein present within each band. Total band signal values of each band were normalized to 
GAPDH, and the fold increase relative to the compliant control sample was plotted (Figure 10B). 
Furthermore, the ratio of phosphorylated FAK to total FAK was calculated, and the fold increase 
relative to the compliant control sample was plotted (Figure 10C). To our surprise, it became 
clear that matrix stiffness does not significantly influence FAK expression or activity. 
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 Based on this finding, we decided to investigate the effect that matrix stiffness and 
treatment with PF573228 has on the phosphorylation of Src Y418. This specific tyrosine residue 
was selected, because its phosphorylation is known to trigger the phosphorylation of VE-
cadherin tyrosine residues 658 and 685, which are mediators of vascular permeability.
51,56,88
 To 
achieve this, the same samples were analyzed using anti-phospho-Src-Y418 and anti-Src 
antibodies (Figure 11A). Because it was not immediately clear whether matrix stiffness or FAK 
inhibition significantly influenced Src expression or phosphorylation, densitometric analysis was 
conducted, normalized to GAPDH, compared to the compliant control samples (Figure 11B), and 
the ratio of phosphorylated Src to total Src was calculated (Figure 11C). Interestingly, from this 
analysis it became clear that while PF573228 does not influence Src expression or activity, 
increases in matrix stiffness significantly affect the phosphorylation of Src tyrosine residue 418. 
 Furthermore, we decided to investigate the effect that matrix stiffness and FAK inhibition 
have on the phosphorylation of VE-Cadherin Y685. To achieve this, samples were analyzed 
using anti-phospho-VE-cadherin Y685 and anti-VE-cadherin antibodies (Figure 12A). Upon 
conducting densitometric analysis (Figure 12B) and calculating the ratio of phosphorylated 
protein (Figure 12C), we were able to determine that increasing matrix stiffness significantly 
increases VE-cadherin phosphorylation within our system. Furthermore, we were also able to 
determine that treatment with PF573228 significantly reduces VE-cadherin phosphorylation. 
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Figure 10: (a) Representative protein bands generated by western blots. 
(b)_Fold increase of total band signal calculated by densitometric analysis. 
(c)_Ratio of phosphorylated FAK Y397 (activated FAK) to total FAK. 
(S)_is stiff gel; 100 mM ribose, (C) is compliant gel; 0 mM ribose 
PF indicates inclusion of 100 nM PF573228, CTRL indicates no inhibitor. 
FAK and FAK Y397 total band signal data normalized to GAPDH. 
Data presented as mean ± standard error, with * indicating P < 0.05. 
 
(A) 
(B)                 (C) 
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Figure 11: (a) Representative protein bands generated by western blots. 
(b)_Fold increase of total band signal calculated by densitometric analysis. 
(c)_Ratio of phosphorylated Src Y418 (activated Src) to total Src. 
(S)_is stiff gel; 100 mM ribose, (C) is compliant gel; 0 mM ribose 
PF indicates inclusion of 100 nM PF573228, CTRL indicates no inhibitor. 
Src and Src Y418 total band signal data normalized to GAPDH. 
Data presented as mean ± standard error, with * indicating P < 0.05. 
 
(A) 
(B)                (C) 
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Figure 12: (a) Representative protein bands generated by western blots. 
(b)_Fold increase of total band signal calculated by densitometric analysis. 
(c)_Ratio of phosphorylated VE-Cadherin Y685  to total VE-Cadherin. 
(S)_is stiff gel; 100 mM ribose, (C) is compliant gel; 0 mM ribose 
PF indicates inclusion of 100 nM PF573228, CTRL indicates no inhibitor. 
VE-cadherin and Y685 total band signal data normalized to GAPDH. Data 
presented as mean ± standard error, with * indicating P < 0.05. 
 
(A) 
(B)                (C) 
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3.5 Additional Experiments 
 Additional experiments were conducted to support the work of others complementary my 
investigation into the effect that matrix stiffness has on vascular permeability. Others in the lab 
have shown that increases in matrix stiffness produce increases in vascular permeability via an 
Evan's blue extravasation assay on spontaneous mammary tumors allowed to stiffen by natural 
means, and on tumors treated with β-aminopropionitrile. BAPN is a widely used inhibitor of 
lysyl oxidase, and treatment with the drug prevents further collagen cross-linking from 
occuring.
89,90
 Though our findings indicated that treatment with BAPN significantly reduces 
vascular permeability, we could not claim that this effect was due to a change in matrix stiffness 
without considering the possibility of it directly affecting endothelial cells. Therefore, we 
evaluated the effect that treatment with 50 ng∙mL-1 and 100 ng∙mL-1 BAPN has on the 
permeability of HUVEC monolayers grown on stiff (10 kPa) PA gels relative to control samples. 
These concentrations were selected based on the result of a qualitative cell viability assay. We 
found that treatment with BAPN had no effect on monolayer permeability (Figure 13). 
 
Figure 13: Normalized intensity ratio of HUVEC 
monolayers seeded on 10 kPa PA gels as a function of 
BAPN concentration, which was found to have no 
significant effect on permeability (ntotal = 66). Data presented 
as mean ± standard error, with * indicating P < 0.05. 
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 Having identified that inhibition of MT1-MMP activity prevents stiffness-induced 
increases in angiogenic outgrowth, our lab decided to investigate the role that matrix stiffness 
plays in MT1-MMP expression and activity. In support of this work, and to verify that our MT1-
MMP inhibitor functioned as intended, we generated three independent sets of HUVEC-infused 
glycated collagen gels, with each set containing sixteen gels, four per each of the following 
conditions: compliant control, compliant with GM6001, stiff control, and stiff with GM6001. We 
helped process these gels in preparation for western blotting experiments, which a colleague ran 
to show that increasing matrix stiffness enhances both MT1-MMP expression and activity. 
Additional gels were prepared for use in an EnSens MMP-14 activity detection kit assay, which 
enabled fluorescent visualization of MT1-MMP activity in live cells via the addition of a 
molecular rotor dye and a substrate containing a dye binding site hidden by a cleavable unit.
91,92
 
These samples were imaged using an Zeiss LSM 880 inverted equipped with a C-Apochromat 
40x/1.2 W Corr M27 water immersion objective (Figure 14). 
 
Figure 14: HUVEC (phase contrast) within 3D glycated 
collagen gel matrix (cyan) infused with EnSens MMP14-
activity detection kit reagents (red). Image taken in 
collaboration with Dr. François Bordeleau. 
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CHAPTER 4 
DISCUSSION 
 Tumors exhibit many characteristics that distinguish them from surrounding 
physiological tissue. Here, we focus on two: abnormal vasculature, and extracellular matrix 
stiffening. In this project, we were interested in investigating and disrupting the relationship 
between tumor stiffening, angiogenic vascularization, and vascular permeability. Previous work 
by our lab indicates that collagen cross-linking, which is the primary driving force behind matrix 
stiffening, is capable of enhancing the angiogenic outgrowth of endothelial cell spheroids.
21,41
 In 
this study, matrix stiffness was controlled via non-enzymatic glycation reactions, which can 
produce a three-fold increase in matrix stiffness without affecting matrix architecture. This 
differs from methods that alter matrix density and composition, which drastically influence 
matrix architecture, porosity, and the number of available integrin binding sites.
38–40
 By applying 
this technique to an existing ex ovo angiogenesis model in which constructs composed of 
collagen gels sandwiched between nylon meshes are grafted to the chorioallantoic membranes of 
chicken embryos, we observed that cross-linked constructs experience significantly enhanced 
angiogenic vascularization, as indicated by an increase in vascular density relative to compliant 
constructs.
83
 This finding suggests that tumor matrix stiffening, driven by increased lysyl oxidase 
expression and secretion, may be partially responsible for the aberration of tumor vasculature.
28
 
 Matrix metalloproteinases are calcium-dependent enzymes capable of degrading 
extracellular matrix proteins, enabling cells to migrate through tissues. MT1-MMP, also referred 
to as MMP-14, is especially relevant to the tumor microenvironment, as it is responsible for 
cleaving collagen, the increased expression and deposition of which is elevated in cancerous 
tissue.
19,27,93
 Interestingly, MT1-MMP expression is also upregulated in tumor tissues, and our 
lab has shown that MT1-MMP activity increases with matrix stiffness.
43,82
 Furthermore, MT1-
MMP has been found to be essential to the ability of endothelial cells to form neovessels.
44
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Based on this information, we were interested in investigating the role of MT1-MMP activity in 
stiffness-sensitive angiogenic outgrowth. Surprisingly, we found that while inhibiting MMP 
activity via treatment with GM6001 has no effect on the vascularization of compliant collagen 
constructs, it eliminates the stimulating effect that cross-linking has on construct vascularization 
ex ovo. Interestingly, active MMP-14 is capable of activating MMP-2 and MMP-9, releasing 
sequestered growth factors, and even promoting the expression of growth factors, including 
VEGF.
43,44,94
 Therefore, MT1-MMP activity may facilitate and promote angiogenesis in stiff 
tissues, such as tumors, both directly and indirectly. 
 With respect to abnormal tumor vasculature, perhaps even more disruptive than excessive 
branching is the onset of hyperpermeability, which yields vessels that leak fluid, which 
accumulates within the interstitial space, resulting in uniformly high tumor interstitial pressures 
that resists flow into the tissue core, diminishes convective extravasation from vasculature within 
the tumor, and which ultimately leads to hypoxia, acidosis, the rise of aggressive metastatic cells, 
and resistance to immune cell entry and functionality.
7–14
 Previous work by our lab revealed that 
arterial intima wall stiffening, as observed in arteriosclerosis, promotes endothelial barrier 
permeability.
45
 As the endothelial cell barrier of angiogenic neovessels and tumor microvessels 
are only surrounded by a thin basement membrane stabilized by pericytes, they are vulnerable to 
the forces imposed by their surrounding extracellular matrix.
48,49,95
 Therefore, we were interested 
in investigating the effect that matrix stiffening has on vascular permeability. In our pursuit of 
quantifying the effect that collagen cross-linking has on vascular leakage, we developed a novel 
ex ovo neovessel permeability assay, which was used, in part, to reveal that vasculature grown 
within stiff tissues are significantly leakier than those grown within compliant ones. This work 
was carried out alongside an in vivo study in which dye extravasation from the tumor vasculature 
of mice, some treated with β-aminopropionitrile, an inhibitor of collagen cross-linking, revealed 
that stiffer tumors experience greater vascular leakage. 
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 It has been well established that VE-cadherin phosphorylation is a prime regulator of 
vascular permeability.
52
 In particular, the phosphorylation of residues Y658 and Y685, which are 
mediated by the phosphorylation of FAK Y397 and Src Y418, leads to the dissociation of p120-
catenin and β-catenin from VE-cadherin, which disrupts cytoskeletal attachment and enables VE-
cadherin internalization.
51–58
 Because recent work by our lab has revealed that matrix stiffening 
disrupts VE-cadherin localization, we decided to investigate the effect that FAK Y397 
phosphorylation inhibition has on stiffness-sensitive vascular permeability.
82
 To achieve this, we 
employed PF573228, an ATP analogue that selectively inhibits FAK Y397 phosphorylation, 
which is currently undergoing anti-cancer preclinical trials.
59,69,70,96
 We began by quantifying the 
effect that FAK inhibition has on monolayer permeability, and found that while treatment has no 
effect on monolayers grown on compliant substrates, it significantly reduces the permeability of 
those grown on stiff ones, with a concentration of 100 nM eliciting the greatest effect. 
 In lieu of data regarding appropriate dosage values for animal experiments, we applied 
1 μM of inhibitor topically to collagen constructs grafted to the chorioallantoic membranes of 
chicken embryos cultured ex ovo, and were surprised to find that treatment with PF573228 
normalized the permeability of neovessels within cross-linked constructs without disturbing 
those within compliant ones. This finding suggests that pre-treating cancer patients with FAK 
inhibitors might enhance the efficacy of existing systemic chemotherapeutics by normalizing 
leaky tumor vessels, and thus alleviating fluid accumulation and flow stagnation. 
 As FAK inhibition alleviated stiffness-induced hyperpermeability, we hypothesized that 
FAK Y397 phosphorylation would increase with matrix stiffness, which in turn would suggest 
that VE-cadherin Y658 and or Y685 phosphorylation would increase with matrix stiffness. 
We were surprised to find that, in our in vitro system, collagen cross-linking does not influence 
FAK activity. For this reason, we decided to investigate Src Y418, as its role as a mediator of 
vascular permeability is regulated by FAK, and as the disruption of FAK Y397 phosphorylation 
prevents the formation of FAK-Src complexes.
51,57,70,71,97
 Interestingly, we found that increasing 
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matrix stiffness significantly enhances Src Y418 phosphorylation, and that FAK inhibition has 
no effect on Src activity. Furthermore, we found that VE-cadherin Y685 phosphorylation 
increased with matrix stiffness in a manner dependent on FAK Y397 phosphorylation. These 
findings suggest that Src activity is responsible for stiffness-sensitive vascular permeability in a 
manner dependent on the phosphorylation of FAK Y397 (Figure 15). 
 
Figure 15: Proposed mechanism to explain stiffness-sensitive permeability in a manner that 
agrees with the presented data. Matrix stiffening promotes the phosphorylation of Src Y418, 
which promotes the phosphorylation of VE-cadherin residues Y658 and or Y685 in a way that 
depends on FAK Y397 phosphorylation. VE-cadherin phosphorylation triggers dissociation of 
p120-catenin and beta-catenin, which localize and stabilize VE-cadherin at cell-cell junctions. 
Inhibiting FAK Y397 phosphorylation with PF573228 alleviates stiffness-sensitive permeability. 
 
  
 
 
 
38 
 
CHAPTER 5 
CONCLUSION 
 Based on the findings of this project, as well as on the work of a colleague, we believe 
that the aberration of tumor vasculature characteristics can be alleviated or prevented by 
inhibiting the formation of collagen cross-links, resulting in tumors that are less aggressive, more 
receptive to treatment, and more vulnerable to immunological attacks. This can be achieved by 
administering inhibitors of the lysyl oxidase family, including BAPN, AB0023, and 
tetrathiomolybdate (TM). BAPN has a history of clinical use outside of cancer therapy, but has 
been reported to cause osteo- and angio- lathyrism, which are characterized by bone deformity 
and aortic aneurysms, respectively.
98–100
 On the other hand, AB0023, a noncompetitive allosteric 
inhibitor of lysyl oxidase-like 2 (LOXL2), is a novel antibody that has been found capable of 
significantly reducing collagen cross-linking within xenograft models; in one study, it was 
reported to be more effective than BAPN in preventing tissue stiffening.
101
 Furthermore, TM, a 
copper chelator, has already passed through a phase I clinical trial, and is currently undergoing 
phase II trials.
102–104
 By disrupting tumor stiffening, we propose that angiogenic vascularization 
would not go awry, and that tumor vessels would not become so leaky as to cause fluid 
accumulation, flow stagnation and reversal, and vessel collapse. 
 We also believe that existing cancer treatment methods can be enhanced via  
pre-treatment with inhibitors of focal adhesion kinase tyrosine residue 397, which we have been 
shown to normalize vascular permeability. As increases in FAK expression and activity have 
been correlated to tumor progression, and as it has been implicated as critical to cancer cell 
growth, survival, motility, transformation, and to angiogenesis itself, it has been considered a 
potential therapeutic target for over a decade.
59,105
 Consequently, over a dozen FAK inhibitors 
many of which disrupt phosphorylation, and some of which disrupt scaffolding functions,  have 
been developed, and are currently undergoing clinical trials.
105
 In this work, we presented 
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evidence indicating that these inhibitors, namely those that target FAK Y397 phosphorylation, 
and those that disrupt FAK's ability to interact or to form complexes with Src, have greater utility 
in cancer therapy than previously realized. For example, PF562261, an analogue of PF573228, 
has already passed a phase I clinical trials, and has even been shown capable of preventing VE-
cadherin Y658 phosphorylation, resulting in improved endothelial cell barrier function .
106,57
 
 To substantiate the results presented here, we propose an investigation into the effects 
that matrix stiffness and PF573228 have on the phosphorylation of VE-cadherin Y658. This 
requires access to the proper anti-phospho-VE-cadherin antibody, which has been discontinued. 
Furthermore, it would be interesting to evaluate the effect that FAK inhibition has VE-cadherin  
localization within endothelial cells grown on stiff substrates, or on those grown within stiff 
constructs. Finally, because we found Src to be responsive to changes in matrix stiffness in a 
FAK-dependent manner, it would be interesting to evaluate the ability of an inhibitor of Src 
Y418 phosphorylation to alleviate or prevent stiffness-sensitive hyperpermeability. Examples of 
such inhibitors include PP1, which has been reported to reduce vascular permeability in vivo, and 
AP23846, which is more potent and more selective toward Y418, but is less frequently used.
58,107
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CHAPTER 6 
FUTURE DIRECTIONS 
 In this project, we have shown that vascularization via angiogenesis occurs to a greater 
extent in stiff tissues relative to compliant ones, and that the vessels grown within stiff tissues are 
significantly leakier than those formed within compliant ones. Expanding upon this finding, we 
believe that it would be interesting to investigate the effects that matrix stiffening would have on 
the characteristics of vasculature established within compliant tissues. As tumors begin as 
relatively compliant masses of cells that stiffen over time and that must co-opt and engulf 
existing vasculature to grow beyond a miniscule size, such a study would reveal the changes in 
the characteristics of the initial vessels.
28,108–110
 Perhaps the most direct way to achieve this 
would be to induce the cross-linking of collagen fibers within compliant constructs post-
vascularization, which itself could be achieved by introducing exogenous members of the lysyl 
oxidase family. For example, in one study, exogenous LOXL2 was used to stiffen collagen-rich 
implants, and it was found that changes in final tensile values, as well as in stiffening kinetics, 
could be controlled by adjusting LOXL2 concentration.
111
 Alternatively, a collagen gel infused 
with photo-cross-linkers could be used.
112
 
 Even more interesting would be an investigation into the reversibility of stiffness-induced 
vascular characteristics. This study could be conducted via the application cross-link-breakers to 
our existing glycated collagen construct model, or via the use of a hydrogel system with tunable 
post-gelation stiffness. Though a literature search failed to identify any lysyl oxidase cross-link-
breakers, a number of advanced glycation end product cross-link-breakers do exist, including 
TRC4186, C36, and ALT-711. TRC4186, an AGE-breaker designed to combat cardiomyopathy 
and nephropathy in diabetics, has undergone phase I clinical trials, and is currently undergoing 
phase II trials in India.
113–115
 C36, also designed to prevent diabetes-associated cardiovascular 
problems, has been shown to break AGE-derived collagen cross-links in vitro and in vivo.
116
 
41 
 
Finally, ALT-711, which passed phase I and II clinical trials under the name Alagebrium, was 
found capable of significantly lowering the stiffness of left ventricle stiffening within the hearts 
of patients over a one year study via the elimination of AGE-derived cross-links.
117
 Alternative 
to the glycated collagen construct model used within this project, an alginate-based hydrogel that 
incorporates reversible cross-links, which is capable of undergoing both stiffening and softening 
as late as two weeks post-gelation in a spatially controlled manner, could be used to evaluate the 
reversibility of stiffness-induced vascular characteristics.
118
 In the context of cancer therapy, if it 
were to be found that reducing tumor stiffness induces a vascular normalization response, then 
perhaps the efficacy of existing cancer treatment methods could be enhanced by incorporating 
pre-treatments that target tumor stiffness. 
 Separate from cancer research, an investigation into the reversibility of stiffness-sensitive 
vascular characteristics might also be of interest to engineers who design tissue constructs. We 
imagine constructs designed with degradable cross-links, which makes them resistant to breaking 
during implantation, and which promotes angiogenic vascularization and cell migration to 
facilitate host-construct integration, but eventually soften to physiological levels.  
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APPENDIX 
A.1 Protocol - Western Blot Sample Preparation  
Mortar and Pestle Preparation - Per endothelial cell infused glycated collagen gel to be 
processed, prepare one mortar and one pestle at least one day prior to sample preparation. 
1. Wash using Alconox, then rinse using MQ water 
2. Submerging in 70% EtOH for 15 minutes, then air dry overnight 
3. Wrap in clean aluminum foil, then autoclave (gravity, 15 minutes) 
4. Place in a sealable plastic bag, then chill overnight at -80oC 
 
Station Preparation - Perform this step immediately prior to sample preparation in a fume hood 
1. Line flat foam trays with paper towels 
2. Place 6x Laemmli buffer on ice, as well as labeled tubes 
3. Fill bucket with 10 scoops of liquid N2 using forceps and a cup 
4. Transfer chilled mortars and pestles from -80oC to lined foam trays 
5. Fill and refill mortars (with pestles inside) with liquid N2 until evaporation slows  
 
Protein Extraction - Begin performing this step while mortars are filled with liquid N2  
1. Transfer samples from -80oC to liquid N2, then from liquid N2 to filled mortars 
2. Immediately following N2 evaporation, crush sample via a few blows with pestle 
3. Add 150 μL 6x Laemmli buffer (per 300 μL gel) to crushed sample, then grind to a powder 
4. As powder begins to melt, stop grinding (can still mash it, but avoid bubble formation) 
5. Once powder is fully liquefied, pour into labeled tubes, flash freeze,  and store at -80oC 
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A.2 Protocol - Chicken Embryo Culture 
Egg Procurement - Account for chicken embryo death when planning experiments (unfertilized 
eggs, dead on arrival, yolk sac rupture during egg cracking, late-stage death, contamination, ...) 
1. Order fertilized White Leghorn chicken eggs designated for research purposes 
At Cornell University, eggs can be ordered via phone at (607) 272 - 8970  
2. Receive eggs at ≤19°C, and store in a cooler maintained at 12.8°C for ≤7 days 
Alternatively, begin at step ED0 upon egg delivery 
Egg Incubator Preparation - Incubators should be cleaned often to avoid contamination 
1. Set the GQF 1500 Professional rocking egg incubator to 37.8°C, and fill the water bath 
Chick Incubator Preparation - Incubators should be cleaned often to avoid contamination 
1. Obtain a Hova-Bator Circulated Air Incubator, which should consist of a two-unit foam 
enclosure, a plastic liquid trap, a wire mesh, a heating unit, and a thermometer 
2. Wash all incubator components using Alconox and water to remove culture residue 
3. Sterilize all incubator components using bleach, followed by a rinse with MQ water 
4. Spray all incubator components with 70% EtOH, then air dry overnight 
5. Adjust heating unit to achieve 37.8°C, add cups of water to achieve 60% relative humidity  
Autoclaved Eggshell Powder Preparation 
1. Rinse uncrushed eggshells using water, then soak in Alconox for a few minutes to detach 
inner-shell membranes, then rinse away membranes and Alconox with warm water 
2. Spray eggshells with 70% EtOH, then air-dry overnight in a chemical fume hood 
3. Grind dry eggshells into a powder using a mortar and pestle, then transfer into a glass beaker 
4. Cover beaker with aluminum foil, then autoclave (30 minutes gravity sterilize) 
5. Transfer autoclaved eggshells into labeled 50 mL tubes in a sterile laminar flow hood 
6. Store autoclaved eggshells at -20°C until time of use 
ED0, Beginning of Culture 
1. Press the "Tuner Automatic" button on the GQF 1500 Professional to disable the rocking 
mechanism, then press and hold the "Tuner Manual" button until the platforms are horizontal 
2. Using a dry cloth, gently scrub residue away from eggs (do not use EtOH) 
3. Place clean eggs in the rocking egg incubator, then press the "Tuner Automatic" button twice 
to re-enable the rocking mechanism 
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ED3, Cracking eggs - Prepare ex ovo culture platforms in batches of 10 to 20 to save time 
If necessary, save eggshells in a 1000 mL beaker for future use (avoid crushing them) 
1. Place a prepared chick incubator nearby the laminar flow cabinet 
2. Sterilize the following items, and place them within a sterile laminar flow cabinet 
a) Absorbent pads (lay them out to form a work surface) 
b) Unopened packaged of Fineline Savvi Serve 405 5 oz. plastic tumblers 
c) 1000 mL beaker filled with warm water 
d) AEP 30510400 Zipsafe Sealwrap 
e) Container for spent egg innards 
f) Rubber bands 
g) Kimwipes 
h) Egg carton 
i) Hacksaw and c-clamp 
j) Autoclaved eggshell powder 
k) Plastic Petri dishes 
1. Add warm water to each cup (≈ 1/3 full, or ≈ 55 mL per cup) 
2. Drape a sheet of plastic wrap over each partially filled cup (leave more than enough slack to 
form a hammock that rests upon the surface of the water, press the seal wrap against the cup 
walls (it will stick to the cup), then secure the hammock in place using a rubber band) 
3. Spray hammocks with 70% EtOH, wipe using a Kimwipe soaked in 70% EtOH, then air dry 
4. Retrieve four eggs from the rocking incubator, spray them using 70% EtOH, place in carton 
horizontally, and incubate for two minutes (embryos will migrate toward the top of the egg) 
5. Preserving the egg's orientation, place it in the c-clamp (contact sides), form a crack along 
the bottom of the shell via a single tap of the hacksaw (albumin should begin to leak), pry it 
open, then gently drop egg contents into the hammock of a culture platform (Figure A.1) 
6. Immediately deposit a small amount of autoclaved eggshell powder to the albumin at the 
periphery of the hammock, cap the culture platform with a Petri dish, then place it in a chick 
incubator (if yolk sac is visibly ripped open, or if egg was unfertilized, or if embryo does not 
possess a heartbeat, then discard the egg contents and the hammock - cup can be reused) 
 
Figure A.1: The ideal crack forms along the lower 
half of the eggshell's circumference. A slightly 
larger perforation should be formed at the very 
bottom to enable the operator to pry the shell open.  
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ED10, Grafting Constructs 
1. Place a chick-containing incubator by the laminar flow cabinet 
2. Sterilize the following items, and place them within a sterile laminar flow cabinet 
a. Aluminum foil (lay it out to form a work surface) 
b. 15 mL tube containing  70% EtOH 
c. Sealed dish containing constructs 
d. Metal tweezers 
e. Marker 
3. Transfer a chick-containing ex ovo culture platform to the laminar flow cabinet 
4. Label the ex ovo culture platform using a permanent marker (Figure A.2) 
5. Use the metal tweezers to place each construct on a predefined section of the chorioallantoic 
membrane (poking or ripping the CAM will trigger an inflammatory response, so be gentle) 
6. Immediately transfer the chick back to the culture incubator 
7. Submerge the metal tweezers in 70% EtOH between chicks 
 
Figure A.2: Grafting positions (place constructs away from the chick, away 
from major blood vessels, and away from the edge of the hammock), 
orientation marking (extend from Petri dish to cup), and labels to include. 
 
≤ ED15, End of Culture 
 
Chicken embryos younger than 10.5 days can be disposed of via suffocation (coating the 
chorioallantoic membrane with oil) or freezing, whereas those older than 10.5 days must be 
decapitated via a single cut with a sharp pair of scissors prior to disposal 
